CD274 and melanoma: Currently, blocking the programmed death 1 (PD-1) and it’s ligand 1 (PD-L1) immune checkpoint signalling to restore anti-tumour immunity has shown unprecedented rates of durable clinical responses in patients, notably in melanoma, renal, lung, prostate and bladder carcinomas [3–6].